GlassScriptPhysician profile
Kenneth Hines
NPI 1215063219
$3,812.24
in general payments reported to CMS, 2019-2025
22 companies · $733 in 2025
The $733 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $514 · 2020: $363 · 2021: $447 · 2022: $281 · 2023: $665 · 2024: $809 · 2025: $733.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,207.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,207.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,156.42 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $550.49 | 2019-2024 | |
| Lilly USA, LLC | $487.79 | 2020-2025 | Mounjaro, Zepbound |
| Novartis Pharmaceuticals Corporation | $268.98 | 2019-2024 | |
| Glaxosmithkline, LLC. | $265.62 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbott Laboratories | $259.78 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Novo Nordisk INC | $227.75 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $132.29 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $80.66 | 2019-2025 | |
| Phathom Pharmaceuticals, INC. | $70.03 | 2024 | Voquezna |
| Janssen Pharmaceuticals, INC | $66.57 | 2019-2021 | |
| Amgen INC. | $54.26 | 2022-2024 | Otezla, Repatha |
| Edwards Lifesciences Corporation | $36.51 | 2022 | |
| Exact Sciences Corporation | $22.58 | 2024 | Cologuard Collection Kit |
| Xeris Pharmaceuticals, INC. | $19.97 | 2023 | Gvoke Hypopen |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $18.72 | 2025 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $17.64 | 2019 | |
| Eisai INC. | $17.35 | 2020 | |
| Stemline Therapeutics INC. | $16.58 | 2023 | Orserdu |
| Paratek Pharmaceuticals, INC. | $15.69 | 2025 | Xhance, Nuzyra |
| Allergan, INC. | $14.68 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $11.88 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Hines listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.